Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson’s disease

BMC Neurology

Diego Santos-García¹  Pablo Martinez-Martin²  Silvia Jesús³  Pablo Mir⁴  Esther Cubo⁵  Teresa de Deus-Fonticoba⁶  Iria Cabo-Lopez⁷  Manual Seijo-Martínez⁷  Itziar Gastón⁸  Nuria Caballol⁹  Maria Asunción Ávila-Rivera⁹  Lydia Vela^1,10  Lluis Planellas^1,11  Luis Manuel López-Díaz^1,12  Maria Álvarez-Sauco^1,13  Lydia López-Manzanares^1,14  Jessica González-Ardura^1,15  Juan García-Caldentey^1,16  Juan Carlos Martínez-Castrillo^1,17  Cristina Prieto-Jurczynska^1,18  Monica Kurtis^1,19  Berta Solano-Vila^2,20  Miquel Aguilar^2,21  Marta Blázquez-Estrada^2,22  Maria Jose Catalán^2,23  Javier Rúiz-Martínez^2,24  Carmen Borrué^2,25  Isabel González-Aramburu^2,26  Pilar Sánchez-Alonso^2,27  Bárbara Vives-Pastor^2,28  Jose Manuel García-Moreno^2,29  Sonia Escalante^3,30  Victor Puente^3,31  Maria Gema Alonso-Losada^3,32  Helena Bejr-Kasem^3,33  Jaime Kulisevsky^3,33  Berta Pascual-Sedano^3,33  Saul Martínez-Horta^3,33  Andrea Horta-Barba^3,33  Jorge Hernández-Vara^3,34  Oriol de Fábregues-Boixar^3,34  Nuria López-Ariztegui^3,35  Caridad Valero-Merino^3,36  Francisco Carrillo-Padilla^3,37 

[1] CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain;Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain;Centro Nacional de Epidemiología y CIBERNED, Instituto de Salud Carlos III, Madrid, Spain;Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain;Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain;Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain;Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain;Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain;Complejo Asistencial Universitario de Burgos, Burgos, Spain;Complejo Hospitalario Universitario de Ferrol (CHUF), Ferrol, A Coruña, Spain;Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain;Complejo Hospitalario de Navarra, Pamplona, Spain;Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain;Fundación Hospital de Alcorcón, Madrid, Spain;Hospital Clínic de Barcelona, Barcelona, Spain;Hospital Da Costa de Burela, Lugo, Spain;Hospital General Universitario de Elche, Alicante, Spain;Hospital La Princesa, Madrid, Spain;Hospital Lucus Augusti, Lugo, Spain;Hospital Quiron Palmaplanas, Clínica Rotger y Centro Neurológico Oms 42, Palma de Mallorca, Spain;Hospital Ramón y Cajal, Madrid, Spain;Hospital Rey Juan Carlos, Madrid, Spain;Hospital Ruber Internacional, Madrid, Spain;Hospital Universitari Josep Trueta y Hospital Santa Caterina, Girona, Spain;Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain;Hospital Universitario Central de Asturias, Oviedo, Spain;Hospital Universitario Clínico San Carlos, Madrid, Spain;Hospital Universitario Donostia, San Sebastián, Spain;Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain;Hospital Universitario Marqués de Valdecilla, Santander, Spain;Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain;Hospital Universitario Son Espases, Palma de Mallorca, Spain;Hospital Universitario Virgen Macarena, Sevilla, Spain;Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Tarragona, Spain;Hospital del Mar, Barcelona, Spain;Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain;Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041, Barcelona, Spain;Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain;Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain;Neurology Department and Neurodegenerative Diseases Research Group, Vall D’Hebron Universitari Campus, Barcelona, Spain;Servicio de Neurología, Complejo Hospitalario Universitario de Toledo, Toledo, Spain;Servicio de Neurología, Hospital Arnau de Vilanova, Valencia, Spain;Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica. Hospital Universitario de Canarias, Tenerife, Spain;

关键词: Parkinson’s disease;    PD-MCI;    Cognition;    Lifestyle;    Coppadis;   

DOI  :  10.1186/s12883-021-02485-1

来源: Springer

【 摘 要 】

BackgroundIdentifying modifiable risk factors for cognitive impairment in the early stages of Parkinson’s disease (PD) and estimating their impact on cognitive status may help prevent dementia (PDD) and the design of cognitive trials.MethodsUsing a standard approach for the assessment of global cognition in PD and controlling for the effects of age, education and disease duration, we explored the associations between cognitive status, comorbidities, metabolic variables and lifestyle variables in 533 PD participants from the COPPADIS study.ResultsAmong the overall sample, 21% of participants were classified as PD-MCI (n = 114) and 4% as PDD (n = 26). The prevalence of hypertension, diabetes and dyslipidemia was significantly higher in cognitively impaired patients while no between-group differences were found for smoking, alcohol intake or use of supplementary vitamins. Better cognitive scores were significantly associated with regular physical exercise (p < 0.05) and cognitive stimulation (< 0.01). Cognitive performance was negatively associated with interleukin 2 (Il2) (p < 0.05), Il6 (p < 0.05), iron (p < 0.05), and homocysteine (p < 0.005) levels, and positively associated with vitamin B12 levels (p < 0.005).ConclusionsWe extend previous findings regarding the positive and negative influence of various comorbidities and lifestyle factors on cognitive status in early PD patients, and reinforce the need to identify and treat potentially modifiable variables with the intention of exploring the possible improvement of the global cognitive status of patients with PD.

【 授权许可】

CC BY